Effects of Aggressive Versus Moderate Glycemic Control on Clinical Outcomes in Diabetic Coronary Artery Bypass Graft Patients
Authors:
- Harold L. LazarHLHarold L. Lazar
- Marie M. McDonnellMMMarie M. McDonnell
- Stuart ChipkinSCStuart Chipkin
- Carmel FitzgeraldCFCarmel Fitzgerald
- Caleb BlissCBCaleb Bliss
- Howard CabralHCHoward Cabral
- 1 September 2011
- journal article
- conference paper
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 254 (3) , 458-464
Abstract
This study sought to determine whether aggressive glycemic control (90–120 mg/dL) would result in more optimal clinical outcomes and less morbidity than moderate glycemic control (120–180 mg/dL) in diabetic patients undergoing coronary artery bypass graft (CABG) surgery. Maintaining serum glucose levels between 120 and 180 mg/dL with continuous insulin infusions decreases morbidity in diabetic patients undergoing CABG surgery. Studies in surgical patients requiring prolonged ventilation suggest that aggressive glycemic control (<120 mg/dL) may improve survival; however, its effect in diabetic CABG patients is unknown. Eighty-two diabetic patients undergoing CABG were prospectively randomized to aggressive glycemic control (90–120 mg/dL) or moderate glycemic control (120–180 mg/dL) using continuous intravenous insulin solutions (100 units regular insulin in 100 mL: normal saline) beginning at the induction of anesthesia and continuing for 18 hours after CABG. Primary end points were the incidence of major adverse events (major adverse events = 30-day mortality, myocardial infarction, neurologic events, deep sternal infections, and atrial fibrillation), the level of serum glucose, and the incidence of hypoglycemic events. There were no differences in the incidence of major adverse events between the groups (17 moderate vs 15 aggressive; P = 0.91). Patients with aggressive control had a lower mean glucose at the end of 18 hours of insulin infusion (135 ± 12 mg/dL moderate vs 103 ± 17 mg/dL aggressive; P < 0.0001). Patients with aggressive control had a higher incidence of hypoglycemic events (4 vs 30; P < 0.0001). In diabetic patients undergoing CABG surgery, aggressive glycemic control increases the incidence of hypoglycemic events and does not result in any significant improvement in clinical outcomes that can be achieved with moderate control. Clinical Trials.gov (ID #NCT00460499)Keywords
This publication has 31 references indexed in Scilit:
- Intensive versus Conventional Glucose Control in Critically Ill PatientsNew England Journal of Medicine, 2009
- The Society of Thoracic Surgeons Practice Guideline Series: Blood Glucose Management During Adult Cardiac SurgeryThe Annals of Thoracic Surgery, 2009
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Clinical experience with tight glucose control by intensive insulin therapyCritical Care Medicine, 2007
- Intensive Insulin Therapy in the Medical ICUNew England Journal of Medicine, 2006
- Tight Glycemic Control in Diabetic Coronary Artery Bypass Graft Patients Improves Perioperative Outcomes and Decreases Recurrent Ischemic EventsCirculation, 2004
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Comparison of Factors Associated With 30-Day Mortality After Coronary Artery Bypass Grafting in Patients With Versus Without Diabetes MellitusThe American Journal of Cardiology, 1998